These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16529524)

  • 1. Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.
    Marenco S; Weinberger DR
    CNS Drugs; 2006; 20(3):173-85. PubMed ID: 16529524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMPA receptor potentiators as cognitive enhancers.
    O'Neill MJ; Dix S
    IDrugs; 2007 Mar; 10(3):185-92. PubMed ID: 17351873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.
    Lees GJ
    Drugs; 2000 Jan; 59(1):33-78. PubMed ID: 10718099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMPA receptor modulators as cognitive enhancers.
    Lynch G
    Curr Opin Pharmacol; 2004 Feb; 4(1):4-11. PubMed ID: 15018832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases.
    Niitsu T; Iyo M; Hashimoto K
    Curr Pharm Des; 2012; 18(7):875-83. PubMed ID: 22288409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease.
    Yamada KA
    Expert Opin Investig Drugs; 2000 Apr; 9(4):765-78. PubMed ID: 11060708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allosteric modulators of AMPA type glutamate receptors a novel gubclass of physiologically active substances].
    Raevskiĭ KS; Eremin KO
    Biomed Khim; 2004; 50(6):523-38. PubMed ID: 15707268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forgetting and remembering. A star-studded search for memory-enhancing drugs.
    Marshall E
    Science; 2004 Apr; 304(5667):36-8. PubMed ID: 15060299
    [No Abstract]   [Full Text] [Related]  

  • 9. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries.
    Nakamura K
    CNS Drug Rev; 2002; 8(1):70-89. PubMed ID: 12070527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive enhancers for the treatment of neuropsychiatric disorders: clinical and preclinical investigations.
    Kantak KM; Hofmann SG
    Pharmacol Biochem Behav; 2011 Aug; 99(2):113-5. PubMed ID: 21316387
    [No Abstract]   [Full Text] [Related]  

  • 11. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
    Murray TK; Whalley K; Robinson CS; Ward MA; Hicks CA; Lodge D; Vandergriff JL; Baumbarger P; Siuda E; Gates M; Ogden AM; Skolnick P; Zimmerman DM; Nisenbaum ES; Bleakman D; O'Neill MJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):752-62. PubMed ID: 12730350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ampakine CX546 bolsters energetic response of astrocytes: a novel target for cognitive-enhancing drugs acting as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators.
    Pellerin L; Magistretti PJ
    J Neurochem; 2005 Feb; 92(3):668-77. PubMed ID: 15659236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Part II. Cognitive domains for pharmacological intervention: implications for neuropsychiatric and neurological illnesses.
    Handb Exp Pharmacol; 2015; 228():157-9. PubMed ID: 26317140
    [No Abstract]   [Full Text] [Related]  

  • 14. Ampakines and the threefold path to cognitive enhancement.
    Lynch G; Gall CM
    Trends Neurosci; 2006 Oct; 29(10):554-62. PubMed ID: 16890999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.
    King MK; Pardo M; Cheng Y; Downey K; Jope RS; Beurel E
    Pharmacol Ther; 2014 Jan; 141(1):1-12. PubMed ID: 23916593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drug development for cognitive enhancement in mental health: challenges and opportunities.
    Insel T; Krystal J; Ehlers M
    Neuropharmacology; 2013 Jan; 64():2-7. PubMed ID: 23145450
    [No Abstract]   [Full Text] [Related]  

  • 17. The Mind Bending Quest for Cognitive Enhancers.
    Arce E; Ehlers MD
    Clin Pharmacol Ther; 2017 Feb; 101(2):179-181. PubMed ID: 27706806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Simultaneous AMPA receptor potentiation and NMDA receptor blockade as strategy for creating effective stimulants for cognitive functions].
    Bachurin SO; Grigor'ev VV; Beznosko BK; Bolkunov AV; Kovalev GI; Proshin AN
    Eksp Klin Farmakol; 2010 Jul; 73(7):6-12. PubMed ID: 20821972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data.
    Black MD
    Psychopharmacology (Berl); 2005 Apr; 179(1):154-63. PubMed ID: 15672275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing and treating cognitive impairment in schizophrenia: current and future.
    Lin CY; Tsai GE; Lane HY
    Curr Pharm Des; 2014; 20(32):5127-38. PubMed ID: 24410565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.